Back to search

Article

Immunization With a RBD/Nucleocapsid Fusion Protein Promotes Neutralizing Antibody-Independent Resistance to the Wild-Type and the Delta Variant of SARS-CoV-2

2022-02-18

Abstract excerpt

We generated a chimeric protein that comprises the receptor binding domain (RBD) from Spike (S) and the nucleocapsid (N) antigens (SpiN) from SARS-CoV-2 . Both vaccinated and COVID-19 convalescent individuals presented memory CD4<sup>+</sup> T and CD8<sup>+</sup> T cell responses to SpiN. In rodents, SpiN elicited a strong IFN -γ response by T cells and high levels of antibodies to the inactivated virus, but no n...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
685b1d42-996f-5471-803a-dceba08429ed
DOI
10.2139/ssrn.4038522
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunization With a RBD/Nucleocapsid Fusion Protein Promotes Neutralizing Antibody-Independent Resistance to the Wild-Type and the Delta Variant of SARS-CoV-2DOI 10.2139/ssrn.4038522
Neutralizing antibody-independent immunity to SARS-CoV-2 in hamsters and hACE-2 transgenic mice immunized with a RBD/Nucleocapsid fusion proteinSemantic proximity
Neutralizing antibody-independent immunity to SARS-CoV-2 in Syrian hamsters and human ACE-2 transgenic mice immunized with a RBD/Nucleocapsid fusion proteinSemantic proximity
The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infectionSemantic proximity
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity
Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motifSemantic proximity
Incorporation of Sars-Cov-2 Spike Ntd to Rbd-Based Vaccine Improves Immunity and Protection Against Viral VariantsSemantic proximity
Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variantsSemantic proximity
Dynamics of Spike-Specific Neutralizing Antibodies Across Five-Year Emerging SARS-CoV-2 Variants of Concern Reveal Conserved Epitopes that Protect Against Severe COVID-19Semantic proximity
A broad-spectrum SARS-CoV-2 RBD vaccine with selected high-impact mutations and novel adjuvant induces durable T cell response and broad protection in mice.Semantic proximity
Molecular Aspects Concerning the Use of the SARS-CoV‑2 Receptor Binding Domain as a Target for Preventive VaccinesSemantic proximity
COVID-19 Variants and Vaccine Development.Semantic proximity
Select a neighboring publication to make it the new centre.